AAP
HUMA icon

Arax Advisory Partners’s Humacyte HUMA Stock Holding History

Arax Advisory Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7K Buy
41,899
+37,779
+917% +$35K ﹤0.01% 3610
2026
Q1 		$2.5K Sell
4,120
-893
-18% -$928 ﹤0.01% 3040
2025
Q4 		$4.82K Sell
5,013
-4,369
-47% -$6.19K ﹤0.01% 2878
2025
Q3 		$16.3K Buy
9,382
+8,382
+838% +$16.4K ﹤0.01% 2369
2025
Q2 		$2.09K Hold
1,000
– – ﹤0.01% 2557
2025
Q1 		$1.71K Sell
1,000
-473
-32% -$1.78K ﹤0.01% 2116
2024
Q4 		$7.44K Sell
1,473
-84
-5% -$416 ﹤0.01% 1593
2024
Q3 		$8.47K Buy
1,557
+774
+99% +$5.1K ﹤0.01% 1489
2024
Q2 		$3.76K Buy
+783
New +$4.08K ﹤0.01% 1714

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's HUMA Position: Q2 2026 in Review

Arax Advisory Partners increased its Humacyte (HUMA) stake by 917% in Q2 2026, buying an estimated $35K and bringing the position to 41,899 shares worth $32.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3610.

Arax Advisory Partners first reported a position in HUMA in Q2 2024 and has held it in 9 quarters since. 162 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Arax Advisory Partners held 41,899 shares of Humacyte worth $32.7K as of Q2 2026.
  • Arax Advisory Partners bought 37,779 Humacyte shares in Q2 2026, an estimated $35K.
  • Humacyte made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3610 holding.
  • Arax Advisory Partners first reported a position in Humacyte in Q2 2024 and has held it in 9 quarters since.
  • 162 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.